Latest It Distribution News

CLINUVEL Pharmaceuticals has completed recruitment for its Phase III trial of SCENESSE® in vitiligo patients with darker skin types, setting the stage for first results in late 2026. Early clinical observations suggest promising repigmentation outcomes.

Zip Co Limited reported robust April trading with over 40% year-on-year growth in US total transaction value, underpinning a strong profitability turnaround and reaffirming its FY25 cash EBTDA guidance of at least $153 million.

First Graphene has secured a multi-year exclusive deal to supply graphene-enhanced masterbatch for safety boots aimed at Southeast Asia’s mining sector, marking a significant step in commercialising advanced materials in industrial apparel.

AUB Group Limited has upgraded its FY25 underlying net profit guidance to the upper end of its previously announced range, buoyed by favourable trading conditions and strategic FX hedging.

Zimi Limited has paused its planned capital raising amid ongoing talks, while revealing strong operational momentum including $1.42 million in open orders and expanded market partnerships.

Alligator Energy has announced a significant upgrade to its Blackbush Deposit uranium resource, increasing the Indicated Mineral Resource by 10% following a successful 2024 drilling campaign. This enhancement strengthens the Samphire Project’s feasibility outlook and supports plans for higher production rates.

Savannah Goldfields has announced a significant new gold Exploration Target at its Red Dam deposit within the Georgetown Project, potentially expanding its resource base and supporting future production plans.

Cardiex Limited has formally lodged its CONNEQT Pulse device with Australia's Therapeutics Goods Administration, marking a critical step toward regulatory approval and market expansion.

Southern Cross Media Group reports robust audio revenue growth exceeding expectations and signals a return to dividends for FY25, underpinned by disciplined cost management.

EZZ Life Science Holdings Limited has announced a fully franked ordinary dividend of AUD 0.02 per share for the six months ending December 2024, signaling steady returns for shareholders.

Biome Australia is expanding its health portfolio with Activated Therapeutics, a new practitioner-only brand launching four evidence-based natural medicine products in Q4 2025.

Sigma Healthcare’s recent merger with Chemist Warehouse Group is delivering strong earnings growth, with Normalised EBIT rising 36% in the first half of FY25. Transaction costs remain significant but the combined group’s outlook appears robust.